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Summary.-The results are reported of a randomized prospective clinical trial
carried out to assess the value of specific active immunotherapy using irradiated
autologous tumour cells in patients with glioblastoma multiforme treated by radical
surgery and post-operative irradiation. The results in 62 patients show no statis-
tically significant difference in survival between the group receiving adjuvant auto-
logous tumour cells and those treated with surgery and radiotherapy alone. All 27
patients receiving tumour cells were dead at 30 months, whereas 7 of the 35 controls
were alive at this time. The results were considered sufficiently discouraging to
abandon the trial at this stage on the grounds that there was sufficient evidence in
this study that the administration of irradiated autologous cells was of no benefit to
patients with high grade astrocytomata.
THE prognosis for patients with glio-
blastoma multiforme (Grades III and IV
astrocytoma), which account for 5000 of
all glial tumours, is generally regarded as
hopeless. The average post-operative
survival is approximately 6 months (Craig,
Dodge and Svien, 1957; Earle, Rentschler
and Snodgrass, 1957). Freinkel and
Gorman (1958) reviewed 219 cases treated
by surgery alone of which only 130% were
still alive at one year. Although complete
excision of a glioblastoma may be accom-
plished in some cases by hemispherectomy
(Matsukado, McCarthy and Kernohan,
1961), the subsequent mental and neuro-
logical deficit is unacceptable.
There is now ample evidence that
post-operative radiotherapy in patients
with glioblastoma multiforme increases
survival, compared with operation alone
(Roth and Elvidge, 1960; Taveras,
Thompson and Pool, 1962; Hitchcock and
Sato, 1964; Jelsma and Bucy, 1969).
Roth and Elvidge (1960) reported a well-
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marked increase in survival with the
combined treatment, compared with
operation alone, even in cases in which
total excision of the tumour appeared to
have been accomplished. It seems clear
that post-operative irradiation can achieve
temporary growth restraint of residual
tumour, with resumption of useful life in
a proportion of patients for a limited
time. Nevertheless, even in the most
favourable circumstances, when extensive
tumour removal has been accomplished
andradicalpost-operativeirradiationgiven,
the 5-year survival rate rarely exceeds 50/O.
Methods ofimproving the effectiveness
of irradiation have been sought but no
useful advance as yet has been achieved.
Heavy particle irradiation (Lawrence,
et al., 1962) and also boron capture
therapy using slow neutrons (Sweet,
Soloway and Brownell, 1961) have attrac-
tive theoretical advantages but their
usefulness has yet to be demonstrated.
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cerebral tumours have been treated in
hyperbaric oxygen (Churchill-Davidson,
1967) but the possible advantage of this
approach in cases of glioblastoma multi-
forme has not been systematically ex-
plored. At the Royal Marsden Hospital
cerebral irradiation under hypothermic
conditions, also with the view to increas-
ing the oxygen effect, was investigated by
Bloch et al. (1966), buit no prolongation of
life in patients with glioblastoma was
demonstrated. Although there has been
increasing interest in the use of cytotoxic
agents for gliomata, the response of high
grade astrocytomata to chemotherapy,
either systemically or by regional per-
fusion, has been disappointing (W;ilson
and Hoshino, 1969).
In recent years there has been renewed
interest in immunotherapy as an adjunct
to orthodox treatment for cancer in man
(Hamilton Fairley, 1969; Currie, 1972).
The present study arose chiefly from the
results of an experiment reported by
Haddow and Alexander (1964). These
workers found that the injection of
irradiated autologous tumour cells in rats
bearing abenzpyreneinducedfibrosarcoma
increased the tumour inhibitory effect of
a single large dose of x-rays. This effect
may be explained on the grounds of
enhanced radiosensitivity of the tumour
cells or, alternatively, stimulation of an
immunological process which destroyed
residual cells following irradiation. The
present paper reports the results of a
controlled clinical trial designed to see
whether the administration of irradiated
autologous tumour cells would improvethe
results of post-operative radiotherapy in
high grade astrocytomata of the cerebral
hemispheres.
MATERIALS AND METHODS
Criteria for case selection for the trial
were: (1) high grade supratentorial astro-
cytoma, (2) age less than 70 years, (3) suit-
ability for craniotomy. All patients had
histologically verified astrocytomata of
Grades III or IVmalignancy according to the
criteria of Kernohan and Sayre (1952). All
tumour sections wereexaininedindependently
by 3 pathologists (Professor N. F. C. Gowing
at the Royal Marsden Hospital and Professor
T. Crawford and Dr M. R. Crompton at St.
George's Hospital).
Treatment consisted of either radical
surgery and post-operative cerebral irradia-
tion (Group 1) or radical surgery and post-
operative cerebral irradiation plus subcuta-
neous injections of irradiated autologous
tumour cells (Group 2). A provisional
diagnosis ofhigh grade astrocytoma was made
at the time of craniotomy and treatment
randomly allocated. If the case fell into
Group 2 as much fresh non-necrotic tumour as
possible was placed in tissue culture medium
199 (Glaxo) and packed in ice for transporta-
tion from the Atkinson Morley's Hospital to
the Royal Marsden Hospital and Institute of
Cancer Research. On arrival, approximately
30 minutes to one hour after surgery, a
frozen section was cut from part of the tissue
sample and examined by Professor Gowing to
exclude bacterial, fungal or other aetiology.
A crude cell suspension wNas prepared imme-
diately from the rest of the tumour material
by cutting it into fragments ofless than 1 mm
diameter with scissors and this was imme-
diately irradiated w%ith a single dose of
15,000 rad (220 kV x-rays, dose rate 800-1000
rad/min) in a flat Petri dish. The aim was to
divide the irradiated tumour cell suspension
into 3 aliquots of approximately 1 ml of
minced tissue, one of which was returned
promptly to the neurosurgical unit for
immediate injection and the others were
stored at -70°C without the addition of a
cryopreservative. In many cases, however,
there was insufficient non-necrotic material
to make up more than one or 2 aliquots for
injection.
The tumour material was injected sub-
cutaneously, using a wide bore needle, into the
anterior aspect of the left thigh as soon as
possible after craniotomy. The remaining
2 aliquots were placed in a 20% solution of
dimethyl sulphoxide in culture medium 199,
in the proportion of one part cell suspension
to 10 parts liquid. The mixture was frozen
at 1 'C/min to -50°C and then stored at
-196°C. If enough cell suspension wias
available, 2 further subcutaneous injections
were given during the course of cerebral
irradiation, the second into the right thigh
when the tumour dose was 1000 rad and the
third into the left thigh at 3000 rad.
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TABLE I.-Glioblastoma Multiforme, Clinical Trial: Case Distribution
Number of patients entered into trial
Post-operative deaths
Radiotherapy elsewhere: excluded
Available for analysis
Histological Grade III
t~ ~ A
Treatment group
Surgery, RT .
Surgery, RT, autologous cells .
Male Female Total
19 10 29
16 4 20
49
75
9 (12%)
4
62
Grade IV
, ~ ~ ~~A
Male Female Total
5 1 6
5 2 7
13
A swab was always cultured from the
stored tumour material immediately before
injection for bacteriological examination to
exclude any infection as a possible cause of
local reactions. Skin testing was also carried
out with intradermal injections of 01 ml of
irradiated tumour material into the anterior
aspect of the left forearm at the time of the
second injection and into the anterior aspect
of the right forearm at the time of the third
injection. Both the intradermal and sub-
cutaneous injection sites were watched care-
fully for local skin reactions and the draining
node areas for evidence ofadenopathy.
Between March 1964 and September 1968,
75 patients were entered into the trial
(Table I). Age distribution is shown in Fig.
30J
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C
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FIG. 1.-Glioblastoma: age distribution of trial
patients.
1. In the group of 27 patients receiving
irradiated autologous tumour cells adequate
material for all 3 injections was available for
only 9. Seventeen patients had oneinjection
given within 2 hours of craniotomy and one
patient had 2 injections.
Radiotherapy.-As soon as recovery from
craniotomy permitted, the patient was trans-
ferred from the Neurosurgical Centre at
Atkinson Morley's Hospital to the Royal
Marsden Hospital. Large volume cerebral
irradiation was planned using a 3-field tech-
nique with wedge filters, an example ofwhich
is shown in Fig. 2. According to the tumour
site the patient was treated in a prone, supine
or lateral head position, whilst wearing a
perspex cast to ensure accurate and repro-
ducible daily treatment. The aim was to
deliver a maximum tumour dose of 5000 rad
in daily fractions (Monday to Friday) over 5
weeks using a 6 million volt linear accelerator.
In some cases the treatment time was pro-
longed because of intercurrent or tumour
related problems.
RESULTS
Of a total of 75 patients entered into
the trial, 9 died before radiotherapy
could be given and 4 were excluded as
they were irradiated elsewhere. Post-
operative mortality was similar in those
who received irradiated tumour cells (4
patients) and those who did not (5
patients). The results oftreatment in the
remaining group confirm the poor prog-
nosis of patients with glioblastoma multi-
forme; (Fig. 3): 66% of the total 62
post-operative survivors died within the
first year after treatment, and only one
patient (a control case; A.G., 060146)
remains alive at the time of analysis
(June 1972).
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6 MeV Linear Accelerator
POST
450 Wedge Filters
ANT
----- Tumour volume
FIG. 2.-Isodose distribution for treatment of right parietal glioblastoma adjusted for obliquity. The dotted line represents the tumour bearing volume with a substantial margin to include infiltration.
The overall survival according to
histological grade (Fig. 4) shows a tran-
sient advantage for Grade III compared
with Grade IV disease, but by 36 months
the results are the same. When the results
are considered in relation to sex (Fig. 5)
there appears to be a slight initial advan-
tage for female patients but again this is
not sustained.
Whereas all patients receiving adju-
vant autologous tumour cells were dead
by 30 months, 20% ofthe control patients
treated by surgery and radiotherapy alone
were alive at that time. The difference,
although perhaps striking, is not statistic-
ally significant (see appendix, and Fig. 9).
None of the 9 patients receiving all 3
injections of irradiated autologus tumour
cells survived to 24 months (Fig. 6).
Since sufficient material was obtained for
all 3 injections it is possible that these
patients had particularly large tumours.
The survival of patients according to
tumour grade is shown in Fig. 7. Both
10 x12
RIGHT LEFT
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Surviva
12 24 36 48 60 72 84 986
Months after Treatment
Fiu. 5. Overall survival of trial patients.
Months after Treatment
FIG. 4.-Survival of trial patients according to histological grade.
0 - 0o_
Survival
Surviv
6 12 18 24 30 36 42 46 34
Months after Treatment
FIG. 5.- Survival of trial patients according to sex.
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100
Surgery/Radiotherapy/
75- Autologous cells (27)
-\ Surgery/Radiotherapy (35)
% 50 Patients receiving 3 injections
Survival of autologous cells (9)
6 12 18 24 30 36 42 48 54 60
Months after Treatment
FIG. 6.-Survival of trial patients according to treatment category. Survival of patients receiving 3 injections of autologous cells is shown separately.
25.
Grade III (No cells) 29 pts.
-o Grade III (Autologous cells) 20 pts.
a *- Grade IV (No cells) 6 pts.
o Grade WV (Autologous cells) 7 pts.
Time after treatment (months)
FIG. 7.-Survival according to histological grade and treatment category.
Grade III and Grade IV cases receiving
irradiated tumour cells had a higher
mortality than the corresponding control
group.
In this series there was a male pre-
dominance over females of almost 3 to
one. The sex distribution in each of the
2 main trial groups differed: in the group
receiving autologous tumour cells 17%
were female, compared with 33% in the
control group. To exclude the possible
influence of sex on treatment results, the
survival of male patients was analysed
separately (Fig. 8). This is in keeping
with the general trend and shows that all
males receiving autologous cells were
dead by 30 months, whereas 12.5% ofthe
group treatedby surgery andradiotherapy
alone were alive at this time. The
difference, however, is not statistically
significant (see appendix).
Quality of life after treatment
Functional status was broadly assessed
as good, moderate or poor (Table II).
Of the entire series, 42% derived little or
no benefit from treatment and 58%
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,ceiv.ing
cells (21)
adiotherapy
(24)
-I
6 12 18 24 30 36 42 48 54 60
Months after Treatment
FIcG. 8. Sturvival of male patients according to treatment category.
TABLE II. Glioblastoma Multiforme, Clinical Trial: Functional Status after Treatment
Goo(d AModerate Poor
Total patients 62 21 (34%) 15 (24%) 26 (42%) Surgery, RT groutp. 35 . 14 (400o) * 7 (20%) 14 (40%) Surgery, RT and autologous cells 27 7 (27%) 8 (300o) 12 (43%)
Status definitioni
Assessment of restults of treatment according to functional stattus.
Three arbitrary functional categories have been defined: Good: return to work and resumption of normal
life; Moderate: ambulant patient, can look after himself, but no return to work; Poor: little or no improve-
ment, patient unable to care for himself.
showed either a partial or good
response: 3400 of patients were able to
resume a normal active life (returning to
work or housekeeping) until the tumour
recurred, following which deterioration
was usually rapid. There was little
difference in functional status after treat-
ment between the " immunotherapy "
and control groups. The following history
illustrates the excellent result which can
sometimes be obtained for a time by treat-
ment in cases of high grade astrocytoma.
A 35-year old concert pianist presented
in August 1965 with a history of speech
difficulty for 18 months and intermittent
epilepsy for 11 weeks. Craniotomy re-
vealed a left temporal glioma which was
incompletely removed. Post-operatively
she received a radical course of irradiation
(5000 rad in 48 days), following which she
was able to resume her career as a concert
pianist for 22 years. In February 1968
difficulty in speech and weakness of the
right hand appeared. Her condition then
deteriorated and she died in July 1968,
3 years after treatment. At autopsy, a
large soft ill-defined greyish tumour
measuringlO x 6 x 6cm wasfoundinthe
left temporal region extending into the left
parietal and frontal lobes. Histology
confirmed recurrent Grade IIIastrocytoma.
Autopsyfindings
The majority of patients died either at
home or in terminal care institutions.
Autopsy examinations were carried out on
10 patients, in 9 of whom there was gross
tumour recurrence, confirmed histo-
logically.
One control patient (E.B., 066110,
Grade III, treated by surgery and radio-
therapy) survived 4 years after treatment
Surviva'
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before developing signs suggesting tumour
recurrence. At initial assessment ventri-
culography and carotid arteriography had
indicated the presence ofa large avascular
space-occupying mass in both frontal
lobes but lying predominantly to the left
side. A large cystic lesion in the left
frontal lobe was confirmed at craniotomy
but the right side was not explored. A
dose of 5000 rad was given to both frontal
lobes in 42 days. Initially the patient's
condition improved and she was able to
resume housework and live a fairly normal
life for almost 3 years. She then devel-
oped symptoms and signs suggesting
tumour reccurrence although the brain
scan, which was originally abnormal, was
then normal. Four years after her initial
irradiation she received an additional
1800 rad to the frontal regions in 17 days
for presumed recurrence, but no improve-
ment was achieved and she died one
month later. Autopsy revealed marked
oedema of the brain with enlargement of
the ventricles and thinning of the cortex.
A partly necrotic cavity 5 cm in diameter
was present in the left frontal lobe and
there was moderate scarring in the right
frontal area but no cystic lesion was found.
Histological examination showed no evi-
dence of residual tumour in either lobe.
The left frontal necrotic cavity was well
defined and surrounded by normal looking
brain. There was no microscopic evidence
of radiation induced necrosis in this lobe
nor in the contralateral lobe, which was
included in the treatment volume, and it
was concluded that the residual tumour
cavity remained inactive but failed to heal
following treatment.
Reactions to injected irradiated autologous
cells
Local reactions at the site of injected
irradiated tumour cells were observed in
6 patients. Another patient developed a
low grade fever (37-38°C) that persisted
for 48 hours after the third injection.
Two of the 6 patients developed limited
local reactions after the one and only
injection of irradiated tumour cells was
given. In the remaining 4 patients, all of
whom received 3 injections, the reactions
appeared after the final injection. The
local reaction consisted of induration, up
to 5 x 4 cm in area, associated in one
patient with transient erythema of the
overlying skin. The induration persisted
in one patient for 2 weeks. Four patients
developed small groin nodes on the side
of the injection and in one of these the
nodes were tender to palpation. The
intradermal skin tests were negative in all
cases.
DISCUSSION
The results reported in both groups of
patients in this study are in agreement
with general experience in treating glio-
blastoma multiforme by conventional
methods. It is clear that injected irra-
diated autologous tumour cells have not
improved the survival of patients treated
by surgery and radiotherapy. Patients
who received irradiated tumour cells
were all dead by 30 months whereas 5
(14%) of the control group survived for
more than 3 years, one patient still being
alive at 72 months. The initial mortality
was equally rapid in both groups.
When the results are analysed accord-
ing to sex there appears to be a transient
advantage for female patients in both
treatment groups. In laboratory experi-
ments differing responses have been ob-
served in male and female rats bearing
chemically induced gliomata, suggesting
that these tumours may be influenced by
hormonal factors (Hopewell and Wright,
1969). The male predominance in human
gliomata and the fact that male patients
tend to die earlier than female patients
(Penman and Smith, 1954) adds support
to this possibility.
Since the work of Foley (1953) and
Prehn and Main (1957), who demonstrated
tumour specific antigens in methylcholan-
threne induced murine sarcomata, it has
become clear that a host response speci-
fically retarding neoplastic cell growth can
be mounted in a variety of viral and
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chemically induced animal tumours as
well as in some spontaneous tumours of
experimental animals (Old and Boyse,
1964; Hammond, Fisher and Rolley,
1967). Sensitized lymphocytes or anti-
bodies which react with autologous tumour
cells in man have been demonstrated in a
number of tumours including Burkitt's
lymphoma (Klein et al., 1967), melanoma
(Lewis et al., 1969), soft tissue sarcomata
(Morton et al., 1968), neuroblastoma
(Hellstrom et al., 1968) and colonic neo-
plasms (Gold, 1967).
An antibody (Ikonopisov et al., 1970)
and lymphocyte (Currie, Lejeune and
Hamilton Fairley, 1971) response against
tumour cells can be demonstrated after
injection of irradiated autologous tumour
cells in patients with malignant melanoma,
but unfortunately this is not associated
with tumour regression. Although im-
mune lymphoid cells taken from patients
or animals with growing tumours may
react against the corresponding tumour
cells in vitro, serum factors exist in vivo
which block the action of immune lym-
phoid cells or tumour antibodies in the
host with cancer (Hellstrom and Hellstrom,
1970; Currie and Basham, 1972).
A recent histological study has re-
ported lymphocytic infiltration in 27 of 77
patients (35%) with Grades III or IV
astrocytomata (Ridley and Cavanagh,
1971). This tissue cellular response may
represent the morphological features of a
host defence mechanism similar to that
seen in other human tumours such as
breast cancer (Hamlin, 1968; Bloom,
Richardson and Field, 1970), neuro-
blastoma (Martin and Beckwith, 1968),
seminoma (Dayan, 1966), and stomach
cancer (Black, Opler and Speer, 1956).
Levy, Mahaley and Day (1972) have
reported that patients with glioblastomata
and other intracranial neoplasms possessed
peripheral blood lymphocytes which were
specifically cytotoxic to cultured auto-
logous tumour cells in vitro. They con-
cluded that both anaplastic and well-
differentiated tumours of the central
nervous system can induce a tumour-
specific, cell-mediated immune response
in the host. However, previous attempts
by this group to develop tumour specific
antisera for treatment of glioblastoma
were unsuccessful (Mahaley and Day,
1965; Mahaley, 1968, 1971). On the
other hand, precipitation between glio-
blastoma extract and the patient's serum
after, but not before, immunization with
autologous tumour extract has been
reported by Trouillas (1971). These
findings have not been supported by the
work of Delpech et al. (1972) who were
unable to demonstrate anti-tumour anti-
body in glioblastoma. In a recent study,
Lim and Kluskens (1972) compared anti-
gens from a rat astrocytoma with those
from normal rat brain and liver using
immunodiffusion and immunoelectropho-
resis and reported the presence ofantigens
that appeared to be specific for the
tumour cells. Clearly, further studies are
required to establish the presence of
tumour associated antigen in human
gliomata.
Immunological investigations ofmalig-
nant gliomata following the administra-
tion of irradiated autologous cells must
take into consideration the antigenicity of
normal brain tissue which may be included
in the injected material, as well as the
influence which the blood-brain barrier
might exert upon cellular and humoral
immune mechanisms. In recent years,
several normal brain-specific antigens have
been identified and partially characterized
although their precise role has not been
elucidated (Hatcher and MacPherson,
1970). It is known that under certain
conditions animals may react immuno-
logically with their own brain tissue and
cause an allergic encephalomyelitis
(Paterson, 1966). Although median sur-
vival in our patients was relatively short,
there was no evidence for a superimposed
acute encephalomyelitis. Under normal
conditions proteins cannot cross theblood-
brain barrier but the presence of tumour,
a surgical procedure, and perhaps also
cerebral irradiation are all situations in
which the blood-brain barrier may no
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longer remain intact and consequently
humoral immune mechanisms may be able
to operate more readily. On the other
hand, if cellular immune mechanisms are
implicated chiefly in immunological
tumour rejection processes and this seems
likely (Alexander and Hamilton Fairley,
1967), then even an intact blood-brain
barrier would not be expected to prevent
the passage of sensitized lymphocytes
which are known tobe capable ofmigrating
through normal vascular endothelium
(Gowans, 1959).
It is possible that immunological
mechanisms operate to prevent metastases
developing outside the central nervous
system. Extra-neurogenic spread from
astrocytomata is an exceedingly rare
occurrence but it is clear from autografting
of viable tumour tissue (Bloom et al.,
1960; Grace et al., 1961) that typical
gliomata can in fact grow at peripheral
implantation sites. The occasional occur-
rence of rapidly growing extracranial
deposits in patients with ventriculo-pleural
or ventriculo-peritoneal shunts (Wolf,
Cowen and Stewart, 1954; Wakamatsu
et al., 1971) suggests that the paucity of
metastases in glioblastoma is due to
mechanical rather than immunological
factors.
Bearing in mind the remarkable
mobility of the lymphocyte, the mere
confinement of cerebral tumours within
the central nervous system would not, per
se, prevent an immunological reaction
from occurring across the blood-brain
barrier. Scheinberg and Taylor (1968)
have demonstrated that rejection of an
intracerebral graft of chemically induced
mouse glioblastoma can be achieved by
immunizing the animal with tumour cells
and Freund's adjuvant. On the other
hand, human glioblastomata are usually
large and invariably incompletely excised,
infiltrating widely and diffusely into brain
substance, and it is likely that any
immunological reaction, either natural or
induced, would be inadequate to control
residual tumour growth. Even if specific
tumour antigenicity is present, excessive
antigen production from a large bulk of
tumour might exhaust or paralyse the
host's immunological defences (Currie and
Basham, 1972). On the other hand,
specific antigenic material may in fact be
lost from gliomata of high grade
malignancy compared with relatively be-
nign tumours of neural origin (WAick-
remesinghe and Yates, 1971), although
this concept is not supported by the
recent work ofLevy et al. (1972) who found
sensitized peripheral lymphocytes in
patients with anaplastic and also
well-differentiated intracranial tumours.
In the 10 patients of the present series
who had multiple injections of irradiated
autologous tumour cells, none showed
positive intradermal skin tests to indicate
the development of a cell-mediated local
reaction against the injected tumour. On
the other hand, in 6 glioblastoma patients,
autografted with viable tumour cells by
Grace et al. (1961), 2 ofthe 4 patients who
rejected their autografts gave strongly
positive wheal reactions with surrounding
flair on skin testing several months later,
whereas 2 patients who developed typical
glioblastoma in their subcutaneous tissue
did not. This suggests that a delayed
hypersensitivity cell-mediated type of
immunological reaction had developed
against the antigens of the grafted cells.
It was impossible to say whether these
antigens were tumour associated or merely
carried by normal brain tissue included in
the injected material.
In the present study, evidence of the
presence of a cellular immune reaction
occurring within inguinal nodes draining
the inoculation site was crudely sought by
palpation but small tender groin nodes
appeared in only one patient. More
recently Anderson et al. (1970) have
studied the histological appearance of the
draining lymph nodes following the injec-
tion of irradiated autologous tumour cells
in 8 patients with carcinoma of the breast
and one patient with carcinoma of the
colon. The findings were compared with
the appearance of nodes removed from
normal controls, subjects whohadtyphoid,
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paratyphoid A and B vaccine injections or
skin allografts and one patient with
varicose eczema. Two of the 9 patients
with cancer showed large numbers of
pyroninophilic blast cells in the nodes.
Similar changes were seen in the 4 skin
allograft recipients and the patient with
varicose eczema; in all the remaining
patients the nodes were normal.
Finally, it is necessary to consider the
possible dangers which may be associated
with attempts at immunotherapy, such as
enhancement oftumour growth which has
been encountered in animal experiments
(Vaage, 1971; Law et al., 1971) reported
after the conclusion of this trial. In most
cases in the present study there was good
clinical evidence oftumour recurrence and
this was proved histologically in 9 of the
10 patients subjected to autopsy. Al-
though the precise cause of death in the
remaining patient (E.B., 066110, see
above) remains obscure, it should be noted
that this patient did not receive autologous
tumour cells but was treated with surgery
and irradiation alone.
Present methods oftreatmentgenerally
fail to achieve more than temporary
growth restraint in the great majority of
patients with glioblastoma multiforme.
Radical surgery and post-operative irra-
diation are capable of eradicating the
tumour in only a very small proportion of
patients, but are often valuable in pallia-
tion. Against this background of thera-
peuticfailureitis relevant to consider ways
in which the management of this tumour
can be made more effective.
Extensive necrotic areas in the tumour
are frequently present and it is probable
that foci ofanoxic malignant cells account,
at least in part, for the failure of radio-
therapy to achieve more than temporary
tumour control. Although the clinical
history in patients with glioblastoma may
be short, tumour growth rate is not
necessarily rapid. The tumour mass is
often large and relatively small changes in
volume within a confined space or involv-
ing important cerebral areas are likely to
be critical in producing functional dis-
turbance. Johnson et al (1960) found
that onlv 0.60o of glioblastoma cells were
synthesizing DNA, indicating that the
proliferating fraction of cells at any given
time was very small. This is consistent
with the presence of a high proportion of
hypoxic non-proliferating cells. Radio-
therapy under hyperbaric oxygen may
therefore on theoretical grounds offer some
advantages, but so far there has been little
enthusiasm for treating gliomata in this
way.
Glioblastoma is a particularly suitable
tumour for assessing the possible advan-
tages of fast neutron therapy, since the
biological effect with this treatment is less
dependent upon cellular oxygenation than
with photon irradiation. So far, chemo-
therapy has had little to offer for this
tumour. A trial of BCNU or CCNU,
alkylating agents which pass the blood-
brain barrier, has proved disappointing in
recurrent cases (Wilson and Hoshino,
1969). The use of cytotoxic agents,
either before or together with cerebral
irradiation, has theoretical advantages
which also need to be explored. In a
recent randomized trial, however, a com-
bination of irradiation and 5-fluorouracil
had no advantage over irradiation alone for
patients with glioblastoma (Edland, Javid
and Ansfield, 1971). Until more effective
cytotoxic or radiosensitizing agents against
these resistant tumours are found there
seemslittlehopeofimproving theprognosis
with adjuvant chemotherapy.
The concept ofclinical immunotherapy
is at present based more on speculation
than fact. Further fundamental research
is needed in this field but should only be
undertaken with caution and in collabora-
tion with those experienced in immuno-
logical work.
Of the therapeutic options available to
us at the present time, we believe that
neutron therapy for glioblastoma would
be worth exploring and a clinical trial to
compare this treatment with super-voltage
x-irradiation is now being planned in
association with Dr Mary Catterall at
Hammersmith Hospital.
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APPENDIX
Details of statistical evaluation
The survival times of individual
patients included in the trial are shown in
Fig. 9 using a logarithmic scale. These
are arranged in 8 groups derived from the
possible combinations of grade, sex and
whether or not the patient received
" immunotherapy ". Nine patients who
did not survive to have radiotherapy or
who received their radiotherapy at hos-
pitals other than the Royal Marsden
Hospital have been omitted; this is
justifiedsincethe surgery andradiotherapy
were identical whether or not the patient
was selected to receive "immunotherapy. "
The use of the logarithmic transforma-
tion in carrying out statistical tests of
significance is appropriate where, as in the
case of survival times, the distribution of
values tends to be positively skew. Fig. 9
MALES GRADE III CONTROLS
(19 patients) 9i7
* * * Alive * 0 *@ * *---- 0 0
MALES GRADE III IMMUNOTHERAPY
(1 7 patients) 1_1 l_
. * S.:.-.
0 -.: 000 0 @00 0 0
FEMALES GRADE III CONTROLS
(10 patients) 13.3
* 0 *.0 0 0 0
*
0
FEMALES GRADE lII IMMUNOTHERAPY
(3 patients) __14.4_l
0@0 0
MALES GRADE WV CONTROLS
(5 patients) 9.2
* 0 .0 0
MALES GRADE IV IMMUNOTHEPAPY
(5 patients) 5.3 I i I
* 0 00
FEMALES GRADE IV CONTROLS
(1 patient) 5.1
5.1
0
FEMALES GRADE IV IMMUNOTHERAPY
(2 patients) 5.3
l l I
0 0
2 3 4 5 6 7 8 9 10 20 30 40 50 60 80 100
Survival time (months)
FIG. 9. Individual survival times plotted on a logarithmic scale by sex, grade of tumour
and treatment group.
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also shows for each group a measure of
location obtained by taking the antilog of
the mean log value of each group. If
the distribution of survival times is log
normal, these measures of location can
be interpreted as estimates of the
population median, i.e. the time by which
500o of patients will have diedl. A 90%O
confidence interval for these values is also
shown.
The variation within the 8 groups was
rather less in the case of patients with
Grade III tumours receiving " immunio-
therapy ", but the differences were not
significant so that a pooled "withiII
group " variance was used (82 - 01322;
S 0 3635; (legrees of freedcom = 54).
The t-tests carriedl ouit were
"Immunotherapy " v Controls
for 4 combinations of sex and grade.
Grade III v Grade I\=
for 4 combinations of sex and treat-
ment.
Male v Female
for 4 combinations of grade and
treatment.
For Grade III tumours females appeared
to fare slightly better than males but the
difference was far from significant. The
survival times for Grade III tumours were
generally longer than for Grade IV
tumours but even in this case differences
between corresponding subgroups were
not significant, largely because of the
paucity of Grade IV tumours in the trial
(there were for example only one Grade IN'
female control and only 2 Grade IV
females receiving " immunotherapy ".
The only difference approaching signifi-
cance was Grade III v Grade IV for males
receiving " immunotherapy " (t - 1*718;
d.f. 54; P (one tail) < 1/20).
Tests of the differences between sur-
vival times for control and " immuno-
therapy " patients were also carried out
with the sexes combined; these again were
not significant. The relevant statistics
were as follows:
Grade III
Controls:
mean (loglot) =1P0350) S 0 3490
Immunotherapy ":
mean (loglot) - 1-0578) (47 d.f.)
difference 0-0228
t 0225; not siginificaint.
Giade IV
Controls:
mean (loglot) 0.9214) S = 0-3834
'Immunotherapy
mean (logo1t) = 0-7218) (11 (l.f.)
lifference = 01996
t _ 0 934; inot significant.
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